GENE ONLINE|News &
Opinion
Blog

Will Biden’s Biomanufacturing Initiative Kill Korean Partnership?

by Max Heirich
Share To
The Biden Administration issued an executive order in September centered on bolstering the United States’ biomanufacturing capabilities. The administration intends the initiative to reduce the United States’ reliance on China for pharmaceuticals. However, this wide-ranging initiative has wide-ranging effects, namely on that of Korea’s Biotech Firms.  With companies like Samsung Biologics and SK Bioscience, Korea is one of the leaders in global CMO and CDMO supply chain, while some officials in Korea remain unfazed by the initiative or even see a benefit to the situation, others remain unconvinced. Contract manufacturing organizations (CMOs) or contract development and manufacturing organizations (CDMOs) are on alert as to whether or not Biden’s efforts to keep China in check will disadvantage them or not. 

GO Prime with only $1.49 now

LATEST
Merck’s KEYNOTE-522 Success; BMS Licenses PRX019, Prothena Gets $80M
2024-06-19
Pie Medical Imaging announces enrollment completion of the FASTIII clinical trial
2024-06-18
Company Presentations at BIO 2024 Inspire Partnering
2024-06-14
GV Regains Compliance with Nasdaq Minimum Bid Price Requirement
2024-06-13
ARPA-H Fast-Tracks Biotech Startups: Funding Insights from BIO 2024 Panel
2024-06-12
Gene Therapy Innovations and Financial Challenges for the Future of Medicine
2024-06-12
BIO Releases DEI Survey in Partnership with Korn Ferry
2024-06-11
EVENT
Scroll to Top